Mission Statement:

Women & Infants Hospital, a teaching hospital of The Warren Alpert Medical School of Brown University, is committed to improving the health and well-being of women and infants and to providing our essential services regardless of ability to pay.

Locations:

The main hospital, which services inpatient and outpatient, is located in Providence, RI.  Offsite infusion centers with provider offices are located in Westerly, RI, Warwick, RI, and Fall River, MA.

Practice Details:

At the Gynecologic-Oncology Clinic there are 7 gynecologic oncologists, 4 nurse practitioners, 4 gynecologic oncology fellows, and 1 nurse navigator.

The Breast Health Center is comprised of 3 medical oncologists, 2 breast fellows, 2 nurse navigators, 5 breast surgeons, and 1 plastic surgeon.

At our main infusion site there are a total of 10 full-time infusion and 3 per-diem nurses. We also have palliative care services embedded in our cancer care services on both the inpatient and outpatient side, genetic counselors, and a Women’s Intimacy and Sexual Health Clinic.

Qualifications/Credentials

Women and Infants is recognized as:

  • A Breast Imaging Center of Excellence, American College of Radiography
  • A Center of Biomedical Research Excellence, National Institutes of Health
  • A member of the National Cancer Institute’s Gynecologic Oncology Group
  • A Brown University/Women & Infants National Center of Excellence in Women’s Health by the U.S. Department of Health and Human Services

Pharmacy Services Staff

Our pharmacy employs 4.5 full time pharmacists and 2 technicians for the purpose of order verification and preparation, along with a sterile products pharmacist, two investigational drug services pharmacists and two oncology pharmacy specialists.

Jenna Solomon works as an oncology pharmacist focused on outpatient oncology care, primarily with patients receiving oral chemotherapy. Britny Rogala is a clinical assistant professor at URI and WIH is her practice site, where she works with the inpatient gyn-onc service and the palliative care clinic.

Dispensing Type

We do not currently have a specialty pharmacy. Our pharmacy services are dedicated to the provision of safe and effective oncology care for our patients.

Services Provided

We provide outpatient infusions at 4 different infusion sites throughout RI and Massachusetts. Given our patient population, we also offer chemotherapy desensitizations and have a dedicated inpatient women’s oncology floor.

Why did you join NCODA?

We joined NCODA because I recognized the importance of their work in contributing to the development of patient resources in collaboration with HOPA, ONS, and ACCC.

How did you become a member?

Considering my job focuses on the care of patients receiving oral chemotherapy, I was quickly drawn to the wealth of information made available through NCODA. As a new oncology pharmacist, I chose to join NCODA in order to take advantage of these wonderful resources, and to also learn from the example of other oncology pharmacists.  

How did you hear about us?

Upon starting my new job at Women and Infants, I was made aware of NCODA through my colleague, Britny Rogala, one of the co-chairs of NCODA’s OCE Committee.

How can NCODA help you?

NCODA can continue to help us to provide resources justifying the use of MID as we work towards creating a similar practice model. We also greatly appreciate all the work that has been done thus far for creating patient education resources.

How would you like to be more involved with NCODA?

I am currently a member of the OCE Committee. For the time being, I have elected to join the Foundational (2nd) Tier to allow myself the opportunity to get fully acclimated to my new job. In the upcoming year, I hope to increase my involvement with the OCE Committee and continue to attend the NCODA national meetings. 

What are some challenges you face now or will face in the future?

A shift towards a practice model that better accommodates patients on oral chemotherapy will be necessary as the number of FDA approved oral chemo agents continues to increase.